rss
Ann Rheum Dis 1998;57:209-213 doi:10.1136/ard.57.4.209
  • Extended reports

HLA-DRB1 typing in rheumatoid arthritis: predicting response to specific treatments

  1. James R O’Della,b,
  2. Barbara S Nepomd,
  3. Claire Hairea,
  4. Vivian H Gersukd,
  5. Lakshmi Gaurd,
  6. Gerald F Moorea,
  7. Walter Drymalskic,
  8. William Palmerc,
  9. P James Eckhoffc,
  10. Lynell W Klassena,b,
  11. Steven Weesc,
  12. Geoffrey Thiele,
  13. Gerald T Nepomd
  1. aDepartment of Internal Medicine, University of Nebraska Medical Center (UNMC), USA, bOmaha Veterans Affairs Medical Center, USA, cAffiliated Rheumatoid Arthritis Investigational Network (RAIN) clinics, USA, dVirginia Mason Research Center (VMRC), Seattle, WA, USA
  1. Dr J R O’Dell, University of Nebraska Medical Center, Department of Internal Medicine, 600 South 42nd Street, Omaha, Nebraska 68198–3025, USA.
  • Accepted 4 March 1998

Abstract

OBJECTIVE To determine the predictive value of shared epitope alleles for response to treatment in patients with rheumatoid arthritis.

METHODS Patients from our previously published triple DMARD study were tested for the presence of shared epitope alleles (DRB1 *0401,0404/0408, 0405,0101, 1001,and 1402). Patients who were shared epitope positive were then compared with those who were negative to see if there was a differential effect on therapeutic response.

RESULTS Shared epitope positive patients were much more likely to achieve a 50% response if treated with methotrexate-sulphasalazine-hydroxychloroquine compared with methotrexate alone (94% responders versus 32%, p<0.0001). In contrast shared epitope negative patients did equally well regardless of treatment (88% responders for methotrexate-sulphasalazine-hydroxychloroquine versus 83% for methotrexate). Additionally, a trend toward an inverse relation of the gene dose was seen for response to methotrexate treatment (p=0.05).

CONCLUSIONS These data suggest that determining shared epitope status may provide clinical information useful in selecting among treatment options.

Footnotes

    This Article

    1. Abstract
    2. Full text
    3. PDF

    Responses

    1. Submit a response
    2. No responses published

    Register for free content

    The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

    Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.